Rebecca Richards, MD, PhD
Assistant Professor, Department of Pediatrics
Division of Pediatric Hematology, Oncology, and Bone Marrow Transplantation
The Richards lab focuses on developing chimeric antigen receptor T (CAR-T) cell therapy for acute myeloid leukemia (AML), a disease that can be difficult to treat and is associated with many treatment-related toxicities. CAR-T cell therapy has revolutionized treatment for patients with B cell malignancies, and is an attractive option for treatment of AML. Despite promising pre-clinical data, translation to patients has been hampered by tumor heterogeneity and the possibility of on-target, off-tumor toxicity to healthy tissues. The Richards lab will engineer next-generation CAR-T cells with improved tumor specificity and will use pre-clinical models to identify critical components of AML tumor cell and CAR-T cell biology that will inform further clinical development.